Drug Profile

ARG 201

Alternative Names: ARG201; Bovine type 1 collagen - arGentis

Latest Information Update: 28 Aug 2017

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Tennessee
Developer arGentis Pharmaceuticals
Class Extracellular matrix proteins; Fibrillar collagens
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Systemic scleroderma
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Systemic scleroderma

Most Recent Events

06 Aug 2015 Phase-II development for scleroderma is ongoing
17 Feb 2009 ARG 201 receives Orphan Drug Status for Systemic scleroderma in the EU
01 Jul 2008 Final efficacy data from a phase II trial in Systemic scleroderma released by arGentis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com